flecainide has been researched along with Diabetes Mellitus in 3 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats." | 3.73 | Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Ito, I | 1 |
| Hayashi, Y | 1 |
| Kawai, Y | 1 |
| Iwasaki, M | 1 |
| Takada, K | 1 |
| Kamibayashi, T | 1 |
| Yamatodani, A | 1 |
| Mashimo, T | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for flecainide and Diabetes Mellitus
| Article | Year |
|---|---|
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
2 other studies available for flecainide and Diabetes Mellitus
| Article | Year |
|---|---|
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus; Diabetes M | 2006 |